Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22464626 | 0.69 | NOTUM (0.40) | KDM4EEGFRMEN1KMT2A | |
| SCHEMBL15742163 | 0.68 | HCAR3 (0.37) | KDM4EEGFRKMT2A | |
| SCHEMBL24837942 | 0.67 | KDM4E (0.65) | KDM4ELMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15742078 | 0.67 | EGFR (0.45) | EGFR | |
| SCHEMBL22680102 | 0.66 | NOTUM (0.42) | KDM4ELMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22680304 | 0.66 | KDM4E (0.48) | KDM4ETMPRSS15LMNAMEN1KMT2A | |
| SCHEMBL29429480 | 0.66 | KDM4E (0.48) | KDM4ETMPRSS15LMNAMEN1KMT2A | |
| SCHEMBL28601851 | 0.66 | KDM4E (0.48) | KDM4ETMPRSS15LMNAMEN1KMT2A | |
| SCHEMBL15742080 | 0.66 | EGFR (0.55) | EGFROPRK1 | |
| SCHEMBL6103200 | 0.65 | SMN1; SMN2 (0.44) | KDM4ELMNAMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308171-A1 | BIFUNCTIONAL INHIBITORS WITH EGFR HAVING A E3 UBIQUITIN LIGASE MOIETY | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308171-A1 | BIFUNCTIONAL INHIBITORS WITH EGFR HAVING A E3 UBIQUITIN LIGASE MOIETY | EGFR, ERBB2, MDM2 | KDM4E 1423/4885EGFR 1/4885TMPRSS15 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.